THIRD Amendment to Collaboration, LICENSE and Option AgreementCollaboration, License and Option Agreement • March 9th, 2021 • Cue Biopharma, Inc. • Pharmaceutical preparations
This Third Amendment to the Collaboration, License and Option Agreement (the “Third Amendment”) is entered into as of October 29, 2019 (the “Third Amendment Effective Date”) by and between Cue Biopharma, Inc., a Delaware corporation, having an address of 21 Erie Street, Cambridge, MA 02139 (“Cue”), and LG Chem Ltd., with its principal place of business at LG Twin Towers, 128, Yeoui-daero, Yeongdeungpo-gu, Seoul, 07336, Republic of Korea (“LGC”). Cue and LGC may be referred to herein individually as a “Party” or collectively as the “Parties”.
FIRST AMENDMENT to THE EXCLUSIVE PATENT LICENSE AND RESEARCH COLLABORATION AGREEMENTExclusive Patent License and Research Collaboration Agreement • March 9th, 2021 • Cue Biopharma, Inc. • Pharmaceutical preparations • New York
This Amendment to the Exclusive Patent License And Research Collaboration Agreement (this “Amendment”) is entered into as of November 9, 2020 (the “First Amendment Effective Date”), by and between CUE BIOPHARMA, INC., a corporation organized and existing under the laws of Delaware (“Company” or “Cue”) and MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws of New Jersey (“Merck”). Cue and Merck may be referred to herein individually as a “Party” or collectively as the “Parties”.
FIRST AMENDMENT TO THE AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • March 9th, 2021 • Cue Biopharma, Inc. • Pharmaceutical preparations
This First Amendment to the Amended and Restated License Agreement (“First Amendment”) is by and between Albert Einstein College of Medicine, Inc., a corporation organized and existing under the laws of the State of New York, having an office and place of business at 1300 Morris Park Avenue, Bronx, New York 10461 (“Licensor”) and Cue Biopharma, Inc., a corporation organized and existing under the laws of the State of Delaware, having an office and place of business at c/o MDB Capital Group LLC, 401 Wilshire Blvd, Suite 1020, Santa Monica, California 90401 (“Licensee”). The effective date of this First Amendment is October 30, 2018 (“First Amendment Effective Date”).
FIRST Amendment to Collaboration, LICENSE and Option AgreementCollaboration, License and Option Agreement • March 9th, 2021 • Cue Biopharma, Inc. • Pharmaceutical preparations
This First Amendment (“First Amendment”), dated as of March 15, 2019 (the “First Amendment Effective Date”), to the Collaboration, License and Option Agreement, dated November 6, 2018 (for purposes of this First Amendment only, the “Original Agreement”, and as amended hereby, the “Agreement”), by and between Cue Biopharma, Inc., a Delaware corporation, having an address of 21 Erie Street, Cambridge, MA 02139 (“Cue”), and LG Chem Ltd., with its principal place of business at LG Twin Towers, 128, Yeoui-daero, Yeongdeungpo-gu, Seoul, 07336, Republic of Korea (“LGC”). Cue and LGC may be referred to herein individually as a “Party” or collectively as the “Parties”.
eighth AMENDMENT TO Collaboration, LICENSE and Option AgreementCollaboration, License and Option Agreement • March 9th, 2021 • Cue Biopharma, Inc. • Pharmaceutical preparations
This Eighth Amendment to the Collaboration, License and Option Agreement (the “Eighth Amendment”) is entered into as of December 7, 2020 (the “Eighth Amendment Effective Date”), by and between Cue Biopharma, Inc., a Delaware corporation, having an address of 21 Erie Street, Cambridge, MA 02139 (“Cue”), and LG Chem Ltd., with its principal place of business at LG Twin Towers, 128, Yeoui-daero, Yeongdeungpo-gu, Seoul, 07336, Republic of Korea (“LGC”). Cue and LGC may be referred to herein individually as a “Party” or collectively as the “Parties”.
Second Amendment to Collaboration, LICENSE and Option AgreementCollaboration, License and Option Agreement • March 9th, 2021 • Cue Biopharma, Inc. • Pharmaceutical preparations
This Second Amendment (“Second Amendment”), dated as of August 5, 2019 (the “Second Amendment Effective Date”), to the First Amendment to Collaboration, License and Option Agreement, dated March 15, 2019 (for purposes of this Second Amendment only, the “First Amended Agreement”, and as amended hereby, the “Agreement”), by and between Cue Biopharma, Inc., a Delaware corporation, having an address of 21 Erie Street, Cambridge, MA 02139 (“Cue”), and LG Chem Ltd., with its principal place of business at LG Twin Towers, 128, Yeoui-daero, Yeongdeungpo-gu, Seoul, 07336, Republic of Korea (“LGC”). Cue and LGC may be referred to herein individually as a “Party” or collectively as the “Parties”.
FOURTH AMENDMENT TO Collaboration, LICENSE and Option AgreementCollaboration, License and Option Agreement • March 9th, 2021 • Cue Biopharma, Inc. • Pharmaceutical preparations
This Fourth Amendment to the Collaboration, License and Option Agreement (the “Fourth Amendment”) is entered into as of December 18, 2019 (the “Fourth Amendment Effective Date”), by and between Cue Biopharma, Inc., a Delaware corporation, having an address of 21 Erie Street, Cambridge, MA 02139 (“Cue”), and LG Chem Ltd., with its principal place of business at LG Twin Towers, 128, Yeoui-daero, Yeongdeungpo-gu, Seoul, 07336, Republic of Korea (“LGC”). Cue and LGC may be referred to herein individually as a “Party” or collectively as the “Parties”.
FIFTH Amendment to Collaboration, LICENSE and Option AgreementCollaboration, License and Option Agreement • March 9th, 2021 • Cue Biopharma, Inc. • Pharmaceutical preparations
This Fifth Amendment to the Collaboration, License and Option Agreement (the “Fifth Amendment”) is entered into as of January 15, 2020 (the “Fifth Amendment Effective Date”) by and between Cue Biopharma, Inc., a Delaware corporation, having an address of 21 Erie Street, Cambridge, MA 02139 (“Cue”), and LG Chem Ltd., with its principal place of business at LG Twin Towers, 128, Yeoui-daero, Yeongdeungpo-gu, Seoul, 07336, Republic of Korea (“LGC”). Cue and LGC may be referred to herein individually as a “Party” or collectively as the “Parties”.
SevenTH Amendment to Collaboration, LICENSE and Option AgreementCollaboration, License and Option Agreement • March 9th, 2021 • Cue Biopharma, Inc. • Pharmaceutical preparations
This Seventh Amendment to the Collaboration, License and Option Agreement (the “Seventh Amendment”) is entered into as of May 14, 2020 (the “Seventh Amendment Effective Date”) by and between Cue Biopharma, Inc., a Delaware corporation, having an address of 21 Erie Street, Cambridge, MA 02139 (“Cue”), and LG Chem Ltd., with its principal place of business at LG Twin Towers, 128, Yeoui-daero, Yeongdeungpo-gu, Seoul, 07336, Republic of Korea (“LGC”). Cue and LGC may be referred to herein individually as a “Party” or collectively as the “Parties”.
SIXTH Amendment to Collaboration, LICENSE and Option AgreementCollaboration, License and Option Agreement • March 9th, 2021 • Cue Biopharma, Inc. • Pharmaceutical preparations
This Sixth Amendment to the Collaboration, License and Option Agreement (the “Sixth Amendment”) is entered into as of February 14, 2020 (the “Sixth Amendment Effective Date”) by and between Cue Biopharma, Inc., a Delaware corporation, having an address of 21 Erie Street, Cambridge, MA 02139 (“Cue”), and LG Chem Ltd., with its principal place of business at LG Twin Towers, 128, Yeoui-daero, Yeongdeungpo-gu, Seoul, 07336, Republic of Korea (“LGC”). Cue and LGC may be referred to herein individually as a “Party” or collectively as the “Parties”.
CUE BIOPHARMA, INC. THIRD AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 9th, 2021 • Cue Biopharma, Inc. • Pharmaceutical preparations • Delaware
This Third Amended and Restated Executive Employment Agreement (“Agreement”), dated as of March 4, 2021 (the “Effective Date”), is made by and between Cue Biopharma, Inc., a Delaware corporation (“Cue” or the “Company”) and Daniel Passeri (“Executive,” and together with Cue, the “Parties”).
